Liu et al. recently used preclinical models of melanoma to investigate the immunogenic function of the MAPK pathway inhibitors trametinib and dabrafenib in combination with immunomodulatory antibodies, including PD-L1/PD-1 and CTLA-4. Here, CD274 is linked to melanoma.